Issue Highlights
Issue Period | 8/12/15-10/12/15 |
Price Band | Rs. 540-550 |
Issue Size(Equity Shares) | 1,16,00,000 |
Issue Size (Rs. crore) | 626-638 |
Issue Type | 100% Book built |
Face Value (Rs.) | 10 |
Listing | BSE,NSE |
Industry | Diagnostic Healthcare Service |
Registrar | Link Intime India Pvt. Ltd. |
Minimum Bid Quantity | 20 |
Maximum Retail Subscription | Rs. 1,98,000 (18 lots) |
BRLM | Kotak Investment banking, City Group Global India Pvt. Ltd. |
Retail discount | Rs. 15 per share |
Issue Details
Offer for Sale:
Promoters’ stake sell: 41,07,355 equity shares
Non-promoter stake sell: 7492645 equity shares
Total offer for sale: 1,16,00,000 equity shares
Fresh Issue: Nil
Equity Shares Outstanding Prior to the Issue: 8,22,69,877 equity shares
Equity Shares Outstanding after the Issue: 8,22,69,877 equity shares
Objects of the Issue
This issue being a pure offer for Sale, no proceeds of the issue shall go towards the company.
Except the listing fees all issue related expense shall be borne by the selling stake holders on proportionate basis.
Company Profile
The company offers diagnostic and related health care tests and services in India through its integrated nationwide network. Its customers are mainly individual patients, hospitals and other healthcare provider and corporate. Dr.Lal Pathlab offers over 3,368 diagnostic and healthcare tests.
The company operates on a ‘hub and spoke’ network model and with a national reference laboratory in New Delhi , 163 other clinical laboratories,1340 patient service centers and over 5,000 pickup points.
Risks & Threats
(1) Diagnostic healthcare industry is highly competitive with competitors like Thyrocare, SRL Diagnostics and Metropolis
(2) Business activities are mainly concentrated in northern and eastern India with 85 % of the total revenue generation coming from these regions
(3) Key source of income is individual patients and Indian health insurance sector not being developed; company’s revenue may vary due to a variety of factors like disposable income etc.
(4) The revenue volumes are impacted by seasons with Monsoon season being top grosser and winter months being slack season
Financial Profile #
Parameter | FY 15 |
PEG (Profit, trailing 4 years) | 1.6 |
Net Profit Margin (%) | 13.74 |
Return on Capital Employed (%) | 45.5 |
Return on Equity (%) | 32.9 |
Total Liability to Net worth | .4 |
Price to Book Value | 14.2 |
Operating Cash to Net Profit | 1.6 |
TIE (Times Interest Earned) | 394.8 |
AR collection Period (Days) | 16.8 |
EV/EBITDA | 29.2 |
M-Cap to Sales | 7.1 |
Current Ratio | 2.5 |
Profit CAGR (%) | 32.6 |
# using upper end of the price-band
Inference
The business model of the company is robust and scalable with the ‘hub and spoke business’ network model. The valuations are though stretched in terms of PEG and EV-to-EBITDA but an awesome profit CAGR of 32 % justifies the premium being charged.
Though presently DLPL’s revenue is mainly attributed to northern and eastern India but its cash-rich business model is favorable for venturing into unexplored areas.
In future more players are supposed to enter in the diagnostic business adding up more competition but rising health awareness coupled with the growing health-insurance penetration shall augur well for this industry.
A discount of Rs. 15 for retail investors makes it an intriguing one.
Comments
Post a Comment